Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

As an essential component of immunotherapy, monoclonal antibodies (mAbs) have emerged as a class of powerful therapeutics for treatment of a broad range of diseases. For central nervous system (CNS) diseases, however, the efficacy remains limited due to their inability to enter the CNS. A platform technology is reported here that enables effective delivery of mAbs to the CNS for brain tumor therapy. This is achieved by encapsulating the mAbs within nanocapsules that contain choline and acetylcholine analogues; such analogues facilitate the penetration of the nanocapsules through the brain-blood barrier and the delivery of mAbs to tumor sites. This platform technology uncages the therapeutic power of mAbs for various CNS diseases that remain poorly treated.

[1]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[2]  M. Gilbert,et al.  Immunotherapy in CNS cancers: the role of immune cell trafficking , 2019, Neuro-oncology.

[3]  Ajazuddin,et al.  Recent advancements in liposomes targeting strategies to cross blood‐brain barrier (BBB) for the treatment of Alzheimer's disease , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[4]  K. Hoang-Xuan,et al.  Clinical trial of blood-brain barrier disruption by pulsed ultrasound , 2016, Science Translational Medicine.

[5]  J. Lachowicz,et al.  ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice , 2014, Molecular Cancer Therapeutics.

[6]  S. Carmichael,et al.  Enzyme‐Responsive Delivery of Multiple Proteins with Spatiotemporal Control , 2015, Advanced materials.

[7]  Rongqin Huang,et al.  Choline‐Derivate‐Modified Nanoparticles for Brain‐Targeting Gene Delivery , 2011, Advanced materials.

[8]  B. Davidson,et al.  Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.

[9]  D. Shah,et al.  Antibody biodistribution coefficients , 2013, mAbs.

[10]  F. Caruso,et al.  Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases , 2018, Advanced materials.

[11]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[12]  P. Lorenzo-Luaces,et al.  Nimotuzumab in combination with radiotherapy in high grade glioma patients , 2014, Cancer biology & therapy.

[13]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[14]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[15]  W. Wick,et al.  Current status and future directions of anti-angiogenic therapy for gliomas. , 2016, Neuro-oncology.

[16]  Aiping Zhu,et al.  Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity , 2013, mAbs.

[17]  M. Westphal,et al.  Nimotuzumab treatment of malignant gliomas , 2012, Expert opinion on biological therapy.

[18]  Jianghong Rao,et al.  Quantum dot/bioluminescence resonance energy transfer based highly sensitive detection of proteases. , 2007, Angewandte Chemie.

[19]  A. Palumbo,et al.  Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives , 2015, Leukemia.

[20]  S. Cramer,et al.  Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients , 2017, Stroke.

[21]  Xiaoli Wei,et al.  Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. , 2011, Angewandte Chemie.

[22]  T. Hori,et al.  Expression and quantitative analysis of matrix metalloproteinase-2 and-9 in human gliomas , 2006, Brain Tumor Pathology.

[23]  Jie Li,et al.  Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins , 2016, Nano Research.

[24]  Eric C. Holland,et al.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas , 2016, Science.

[25]  N. Unwin,et al.  Refined structure of the nicotinic acetylcholine receptor at 4A resolution. , 2005, Journal of molecular biology.

[26]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[27]  R. Kiss,et al.  Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. , 2008, Neoplasia.

[28]  J. Ahn,et al.  A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib , 2015, Clinical Cancer Research.

[29]  Huile Gao,et al.  Progress and perspectives on targeting nanoparticles for brain drug delivery , 2016, Acta pharmaceutica Sinica. B.

[30]  M. Kenney,et al.  Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. , 2015, Nanoscale.

[31]  M. Solano,et al.  Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients With Advanced Epithelial-Derived Cancer , 2003, Journal of immunotherapy.

[32]  W. Pardridge,et al.  Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Freskgård,et al.  Antibody therapies in CNS diseases , 2017, Neuropharmacology.

[34]  Michael Weller,et al.  Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.

[35]  W. Banks,et al.  Routes for the delivery of insulin to the central nervous system: A comparative review , 2019, Experimental Neurology.

[36]  H. Kitano,et al.  A comprehensive pathway map of epidermal growth factor receptor signaling , 2005, Molecular systems biology.

[37]  L. Dwoskin,et al.  Active Transport of High-Affinity Choline and Nicotine Analogs into the Central Nervous System by the Blood-Brain Barrier Choline Transporter , 2003, Journal of Pharmacology and Experimental Therapeutics.

[38]  Mingyuan Gao,et al.  Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier. , 2012, ACS nano.

[39]  Ran Mo,et al.  Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. , 2017, Nature nanotechnology.

[40]  R. A. Evans,et al.  Lysophosphatidic acid and amitriptyline signal through LPA1R to reduce P-glycoprotein transport at the blood–brain barrier , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[41]  L. Lampson.  Monoclonal antibodies in neuro-oncology , 2011, mAbs.

[42]  S. Bhatia,et al.  Neuron-Targeted Nanoparticle for siRNA Delivery to Traumatic Brain Injuries. , 2016, ACS nano.

[43]  Chen Jiang,et al.  Choline transporter-targeting and co-delivery system for glioma therapy. , 2013, Biomaterials.

[44]  Xiaoli Wei,et al.  A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. , 2015, Angewandte Chemie.

[45]  K. Jain.  A Critical Overview of Targeted Therapies for Glioblastoma , 2018, Front. Oncol..

[46]  P. Lockman,et al.  The Transport of Choline , 2002, Drug development and industrial pharmacy.

[47]  A. Rauth,et al.  Two‐Step Targeted Hybrid Nanoconstructs Increase Brain Penetration and Efficacy of the Therapeutic Antibody Trastuzumab against Brain Metastasis of HER2‐Positive Breast Cancer , 2018 .

[48]  K. Scearce-Levie,et al.  Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates , 2014, Science Translational Medicine.

[49]  W. Banks,et al.  Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. , 2014, Pharmacology & therapeutics.

[50]  J. Scherrmann,et al.  CNS Delivery Via Adsorptive Transcytosis , 2008, The AAPS Journal.

[51]  Shay Sherbo,et al.  Successful intracranial delivery of trastuzumab by gene‐therapy for treatment of HER2‐positive breast cancer brain metastases , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[52]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[53]  J. Bergerat,et al.  Clinical pharmacology of trastuzumab. , 2008, Current clinical pharmacology.

[54]  U. Krengel,et al.  Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. , 2009, Cancer research.

[55]  J. Sarkaria,et al.  Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. , 2016, Neuro-oncology.

[56]  G. Linette,et al.  CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges , 2018, Neuro-oncology.

[57]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[58]  F. Du,et al.  Nanoparticles of 2-deoxy-D-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. , 2014, Biomaterials.

[59]  P. Diot,et al.  Nebulization as a delivery method for mAbs in respiratory diseases , 2015, Expert opinion on drug delivery.

[60]  Thomas Knobloch,et al.  Targeting the insulin receptor: nanoparticles for drug delivery across the blood–brain barrier (BBB) , 2011, Journal of drug targeting.